Skip to main content
Signal8
Launch Terminal

Vor Biopharma Inc. (VOR)

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Vor Biopharma Inc. logo

Vor Biopharma Inc.

NASDAQ:VORHealthcare
-5.88%$19.68
AH$19.75+0.36%vs close
Mkt Cap$1.21B
Float42.24M
O/S61.43M
Vol
$ Vol
RVOL
Inst Own79.0%
SI17.6%
Earnings
Dilution
Vor Biopharma Inc. logoNASDAQ:VOR$19.68-5.88%
Upcoming Catalysts
Phase Distribution
7 lead-sponsored trials·2 active·0 completed
Phase 1/22
Phase 34
Not applicable1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Terminated

    A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

    Telitacicept, Placebo

    Systemic Lupus Erythematosus

    Enrollment
    91
    Start
    Jun 2022
    Primary Completion
    Jan 2025
    Completion
    Jan 2025
    NCT05306574
  • Phase 3
    Withdrawn

    A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

    Telitacicept, Placebo

    Systemic Lupus Erythematosus

    Enrollment
    0
    Start
    Sep 2024est.
    Primary Completion
    Jan 2025
    Completion
    Jan 2025
    NCT06456567
  • Phase 3
    Active, not recruiting

    A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

    Telitacicept, Placebo

    Generalized Myasthenia Gravis

    Enrollment
    191
    Start
    Jul 2024
    Primary Completion
    Mar 2027est.
    Completion
    Jan 2029est.
    NCT06456580
  • Phase 3
    Recruiting

    Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

    Telitacicept, Placebo

    Primary Sjogren's Disease

    Enrollment
    250
    Start
    Feb 2026
    Primary Completion
    Dec 2028est.
    Completion
    Jan 2029est.
    NCT07404865
  • Phase 1/2
    Terminated

    Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

    VOR33, Mylotarg

    Leukemia, Myeloid, Acute, Myelodysplastic Syndromes

    Enrollment
    67
    Start
    Dec 2021
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT04849910
  • Phase 1/2
    Terminated

    Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

    VCAR33

    Leukemia, Myeloid, Acute

    Enrollment
    38
    Start
    Dec 2023
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT05984199
  • Observational
    Terminated

    A Long-term Follow-up Study of Patients Who Received VOR33

    VOR33

    Leukemia, Myeloid, Acute

    Enrollment
    10
    Start
    Apr 2022
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT05309733
Search ClinicalTrials.gov for “Vor Biopharma”